Tag Archives: Biomedcentral

Holtzbrink Systematically Retracts Science Critical of Vaccines

The Nazi-built Holtzbrinck Publishing Group systematically scrubs any paper that casts vaccines in a negative light. Look at the case of a 2016 animal study of HPV vaccine from Japan.

Like many animal studies in medicine, the purpose is to learn more about a disease in humans by replicating its symptoms in animals. That is what scientists sought to do in this study published in Scientific Reports:

In the case of the human papillomavirus (HPV) vaccine, an unexpectedly novel disease entity, HPV vaccination associated neuro-immunopathetic syndrome (HANS), has been reported and remains to be carefully verified. To elucidate the mechanism of HANS, we applied a strategy similar to the active experimental autoimmune encephalitis (EAE) model – one of the most popular animal models used to induce maximum immunological change in the central nervous system.

Then suddenly in 2018, the Publisher retracted the paper by totally lying about the study’s purpose:

The Publisher is retracting this Article because the experimental approach does not support the objectives of the study. The study was designed to elucidate the maximum implication of human papilloma virus (HPV) vaccine (Gardasil) in the central nervous system. However, the co-administration of pertussis toxin with high-levels of HPV vaccine is not an appropriate approach to determine neurological damage from HPV vaccine alone. The Authors do not agree with the retraction.

The study never said its objective was to “determine neurological damage from HPV vaccine alone,” but to “elucidate the mechanism of HANS [novel disease entity, HPV vaccination associated neuro-immunopathetic syndrome].” This retraction totally lied about the study’s objectives; no wonder the authors don’t agree with it!

The publisher, not the journal, retracted the post. The publisher of Scientific Reports is Nature Publishing Group, which also retracted this 2000 paper on developmentally impaired children. It did so simply because it included children in the 1998 vaccine-autism paper retracted by The Lancet. The retractions cited a medical circus hearing that punished the lead author of both papers for the following:

 b. You knew or ought to have known that your reporting in the Lancet paper of a temporal link between the syndrome you described and the MMR vaccination, Admitted and found proved i. had major public health implications, Admitted and found proved ii. would attract intense public and media interest, Admitted and found proved

Nature Publishing Group is owned by Holtzbrinck Publishing Group, which also owns BioMedCentral. That publisher retracted a 2014 study for linking measles-mumps-rubella vaccination to autism and for the author’s opinion being that vaccination causes autism:

A reader flagged that there were undeclared competing interests related to the article: the author, Dr Hooker, was on the Board of Directors for Focus Autism which supports the belief that MMR vaccine causes autism.  We were concerned enough about the allegations and the content to remove it from the public domain immediately because of the potential harm to public health

Holtzbrinck also owns Frontiers. When the first vaccinated versus unvaccinated study of autism was accepted for publication by Frontiers in Public Health, the vaccine troll army responded. Frontiers took down the study abstract and cancelled publication explicitly in response to vaccine crybabies on the internet.

The study was since published elsewhere, but there is an ongoing theme. Whether it’s the HPV vaccine, the MMR vaccine, or vaccinations in general, Holtzbrinck censors vaccine risk papers. Avoid publishing in its journals like the plague.

BioMedCentral Admitted to Scientific Fraud, Cover-Up of Vaccine-Autism Link By Pulling Brian Hooker’s Reanalysis

Maria Kowalczuk, “Research Integrity Manager” for Springer Nature – overseer of BMC

In the below 2016 email to Committee on Publication Ethics (COPE)’s Iraxte Puebla, Dr. Maria Kowalczuk revealed that her publisher BioMedCentral committed scientific misconduct. In particular, she stated they deleted Dr. Brian Hooker’s MMR-autism reanalysis because his results implicated vaccines in causing autism. She also fabricated non-existent conflict of interest policies that he “broke.” And finally, she lied that his paper was subjected to post-publication “peer review” when it was summarily retracted after they demanded he conduct multiple studies!

Despite all that, Committee on Publication Ethics would later state that BioMedCentral “acted appropriately.” COPE’s chair is an adviser of the “research integrity” committee that Kowalczuk oversees.

Dear Iratxe,

Thank you for bringing this second complaint to our attention. We have reviewed our handling of this case and related correspondence again and we are of the view that BioMed Central has adhered to COPE Code of Conduct and COPE guidelines. As this complaint has not been brought by the author himself we are limited in what information can be divulged to a third party.

With regard to the specific questions from COPE, we provide a summary of our handling of the case below:

  • The article was received on April 17th 2014 and  published on August 27th 2014 in the journal Translational Neurodegeneration.

The article reanalysed CDC data and claimed to show a positive association between MMR vaccination and the risk of autism in Afro-American boys.

  • A reader flagged that there were undeclared competing interests related to the article: the author, Dr Hooker, was on the Board of Directors for Focus Autism which supports the belief that MMR vaccine causes autism.  We were concerned enough about the allegations and the content to remove it from the public domain immediately because of the potential harm to public health, and posted this message in its place as a temporary measure:

This article has been removed from the public domain because of serious concerns about the validity of its conclusions. The journal and publisher believe that its continued availability may not be in the public interest. Definitive editorial action will be pending further investigation.

The author was informed of this plan before we removed the article.

  • Our investigation concluded that the author did have an undeclared competing interest. We also found that the peer reviewers were also likely to have undeclared competing interests.
  • On August 29th, we removed the above notice,  reinstated the article and published this expression of concern:

The Publisher of this article [1] has serious concerns about the validity of its conclusions because of possible undeclared competing interests of the author and peer reviewers. The matter is undergoing investigation. In the meantime, readers are advised to treat the reported conclusions of this study with caution.

Further action will be taken, if appropriate, once our investigation is complete.

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4150057/

The author was informed before we posted this Expression of Concern.

  • We obtained a further, independent expert peer review of the article because we were concerned about the original peer reviewers’ potential competing interests. That further peer reviewer reported concerns about the statistical methods used. We decided to retract the ­­­­­article with this notice on 3rd October 2014:

The Editor and Publisher regretfully retract the article [1] as there were undeclared competing interests on the part of the author which compromised the peer review process. Furthermore, post-publication peer review raised concerns about the validity of the methods and statistical analysis, therefore the Editors no longer have confidence in the soundness of the findings. We apologise to all affected parties for the inconvenience caused.

http://translationalneurodegeneration.biomedcentral.com/articles/10.1186/2047-9158-3-22

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4128611/

The author was given an opportunity to respond to all the concerns raised and was informed before we retracted the article.

Our actions were in accordance with the COPE guidelines.

 

We provide a point by point response to Mr Crosby’s specific points below:

“Publishers should work with journal editors to:

  • Set journal policies appropriately and aim to meet those policies, particularly with respect to:
    – Editorial independence

All the actions were taken in consultation with and with the explicit agreement of the Editor-in-Chief of Translational Neurodegeneration. Editorial independence was not undermined at any stage.

– Research ethics, including confidentiality, consent, and the special requirements for human and animal research

None of the above were raised as issues in the course of the investigation.
– Authorship

No authorship issues were raised in the course of the investigation.
– Transparency and integrity (for example, conflicts of interest, research funding, reporting standards

We took action to ensure integrity of the published record in light of the concerns regarding conflicts of interest and the methods and statistical analysis that came to light after publication of the article. We acted in a transparent way throughout the process.


– Peer review and the role of the editorial team beyond that of the journal editor

External post publication peer review, that involved the editor, was conducted when concerns were raised about the article.
– Appeals and complaints

  • Communicate journal policies (for example, to authors, readers, peer reviewers)
    • Review journal policies periodically, particularly with respect to new recommendations from the COPE
    • Code of Conduct for Editors and the COPE Best Practice Guidelines
    • Maintain the integrity of the academic record”

BioMed Central policies comply with COPE recommendations and are accessible on our website. We regularly review issues that might affect our polices (sometimes in collaboration with COPE) and update our policies as necessary. Our Editors are required to follow our Code of Conduct for Editors and COPE Best Practice Guidelines. BioMed Central has a team dedicated to dealing with research integrity issues and maintaining the integrity of the scientific record.

Please do let us know if you need any further information or clarification.

With best wishes,

Maria

 

Maria Kowalczuk, PhD 
Biology Editor,

Research Integrity Group 

BioMed Central

Floor 6, 236 Gray’s Inn Road
London, WC1X 8HB

+44 20 3192 2000 (tel)               

+44 20 3192 2010 (fax)

E-mail: Maria.Kowalczuk@biomedcentral.com